Effect of factor VIII and FVIII/PC ratio on portal vein thrombosis in liver cirrhosis: a systematic review and meta‑analysis.
FVIII
Liver cirrhosis
Meta-analysis
PVT
Risk factor
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
09
06
2024
accepted:
02
09
2024
medline:
20
9
2024
pubmed:
20
9
2024
entrez:
19
9
2024
Statut:
epublish
Résumé
To date, there is an ongoing debate regarding the ability to predict PVT development using markers of FVIII or FVIII/PC ratio. This study presents evidence-based medical findings on the influence of FVIII activity levels and FVIII/PC values in the formation of PVT in cirrhosis. The search for original studies on risk factors for portal vein thrombosis (PVT) associated with cirrhosis was conducted, which primarily focused on comparing circulating FVIII activity levels or FVIII/PC ratio in cirrhotic patients with and without PVT. The quality of evidence from each study was assessed using the Newcastle-Ottawa Scale. The meta-analysis included a total of 10 original studies. In total, 2250 cirrhotic patients were included, with 414 having PVT and 1836 without PVT. The pooled analysis using a random-effects model showed no significant difference in standardized mean difference (SMD) for FVIII activity levels in cirrhotic patients with or without PVT (SMD = 0.12, 95% CI=-0.46 to 0.70, P = 0.68), but there was significant heterogeneity (I In conclusion, the FVIII/PC ratio not only reflects the severity of liver disease, but also can be used as one of the predictors of PVT development.
Sections du résumé
BACKGROUND
BACKGROUND
To date, there is an ongoing debate regarding the ability to predict PVT development using markers of FVIII or FVIII/PC ratio. This study presents evidence-based medical findings on the influence of FVIII activity levels and FVIII/PC values in the formation of PVT in cirrhosis.
METHODS
METHODS
The search for original studies on risk factors for portal vein thrombosis (PVT) associated with cirrhosis was conducted, which primarily focused on comparing circulating FVIII activity levels or FVIII/PC ratio in cirrhotic patients with and without PVT. The quality of evidence from each study was assessed using the Newcastle-Ottawa Scale.
RESULTS
RESULTS
The meta-analysis included a total of 10 original studies. In total, 2250 cirrhotic patients were included, with 414 having PVT and 1836 without PVT. The pooled analysis using a random-effects model showed no significant difference in standardized mean difference (SMD) for FVIII activity levels in cirrhotic patients with or without PVT (SMD = 0.12, 95% CI=-0.46 to 0.70, P = 0.68), but there was significant heterogeneity (I
CONCLUSION
CONCLUSIONS
In conclusion, the FVIII/PC ratio not only reflects the severity of liver disease, but also can be used as one of the predictors of PVT development.
Identifiants
pubmed: 39300356
doi: 10.1186/s12876-024-03399-1
pii: 10.1186/s12876-024-03399-1
doi:
Substances chimiques
Factor VIII
9001-27-8
Biomarkers
0
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
320Subventions
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Organisme : Natural Science Foundation of Hebei province,China
ID : H2023206042
Informations de copyright
© 2024. The Author(s).
Références
Zanetto A, Northup P, Roberts L, Senzolo M. Haemostasis in cirrhosis: understanding destabilising factors during acute decompensation. J Hepatol. 2023;78(5):1037–47. https://doi.org/10.1016/j.jhep.2023.01.010 .
Sinegre T, Duron C, Lecompte T, et al. Increased factor VIII plays a significant role in plasma hypercoagulability phenotype of patients with cirrhosis. J Thromb Haemost. 2018;16(6):1132–40. https://doi.org/10.1111/jth.14011 .
doi: 10.1111/jth.14011
pubmed: 29577605
Praktiknjo M, Trebicka J, Carnevale R, et al. Von Willebrand and factor VIII portosystemic circulation gradient in cirrhosis: implications for portal vein thrombosis. Clin Transl Gastroenterol. 2020;11(2):e00123. https://doi.org/10.14309/ctg.0000000000000123 .
doi: 10.14309/ctg.0000000000000123
pubmed: 32032127
pmcid: 7145026
Intagliata NM, Caldwell SH, Tripodi A, Diagnosis. Development, and treatment of portal vein thrombosis in patients with and without cirrhosis. Gastroenterology. 2019;156(6):1582–e15991. https://doi.org/10.1053/j.gastro.2019.01.265 .
Scheiner B, Balcar L, Nussbaumer RJ, et al. Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. J Hepatol. 2022;76(5):1090–9. https://doi.org/10.1016/j.jhep.2021.12.038 .
Qi X, Chen H, Han G. Effect of antithrombin, protein C and protein S on portal vein thrombosis in liver cirrhosis: a meta-analysis. Am J Med Sci. 2013;346(1):38–44. https://doi.org/10.1097/MAJ.0b013e31826485fc .
doi: 10.1097/MAJ.0b013e31826485fc
pubmed: 23187296
Fimognari FL, De Santis A, Piccheri C et al. Evaluation of D-dimer and factor VIII in cirrhotic patients with asymptomatic portal venous thrombosis. J Lab Clin Med. 2005;146(4): 238 – 43. https://doi.org/10.1016/j.lab.2005.06.003
Chen H, Qi X, He C, et al. Coagulation imbalance may not contribute to the development of portal vein thrombosis in patients with cirrhosis. Thromb Res. 2013;131(2):173–7. https://doi.org/10.1016/j.thromres.2012.11.003 .
Tang W, Wang Y, Zhao X, et al. Procoagulant imbalance aggravated with falling liver function reserve, but not associated with the presence of portal vein thrombosis in cirrhosis. Eur J Gastroenterol Hepatol. 2015;27(6):672–8. https://doi.org/10.1097/MEG.0000000000000352 .
doi: 10.1097/MEG.0000000000000352
pubmed: 25923942
Lancellotti S, Basso M, Veca V, et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. Intern Emerg Med. 2016;11(7):959–67. https://doi.org/10.1007/s11739-016-1467-x .
doi: 10.1007/s11739-016-1467-x
pubmed: 27220954
Kalambokis GN, Oikonomou A, Christou L, Baltayiannis G. High Von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosis. Hepatology. 2016;64(4):1383–5. https://doi.org/10.1002/hep.28703 .
doi: 10.1002/hep.28703
pubmed: 27348208
Ren W, Zhang J, Chen Y, et al. Evaluation of Coagulation, Fibrinolysis and endothelial biomarkers in cirrhotic patients with or without portal venous thrombosis. Clin Appl Thromb Hemost. 2020;26:1076029620982666. https://doi.org/10.1177/1076029620982666 .
doi: 10.1177/1076029620982666
pubmed: 33356499
pmcid: 7768576
Turon F, Driever EG, Baiges A, et al. Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors. J Hepatol. 2021;75(6):1367–76. https://doi.org/10.1016/j.jhep.2021.07.020 .
Lopez-Gomez M, Llop E, Puente A, et al. Non-malignant portal vein thrombosis in a cohort of cirrhotic patients: incidence and risk factors. Hepatol Res. 2021;51(10):1064–72. https://doi.org/10.1111/hepr.13703 .
doi: 10.1111/hepr.13703
pubmed: 34324766
Sacco M, Tardugno M, Lancellotti S, et al. ADAMTS-13/von Willebrand factor ratio: a prognostic biomarker for portal vein thrombosis in compensated cirrhosis. A prospective observational study. Dig Liver Dis. 2022;54(12):1672–80. https://doi.org/10.1016/j.dld.2022.06.004 .
Jiang S, Ai Y, Fan X, et al. Increased factor VIII activity is predictive of the occurrence of portal vein thrombosis in cirrhosis. Thromb Haemost. 2023;123(7):714–22. https://doi.org/10.1055/a-2052-9381 .
doi: 10.1055/a-2052-9381
pubmed: 36913976
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https://doi.org/10.1136/bmj.n71 .
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Han J, Ding Y, Shu Q, et al. Contribution of coagulation imbalance in development of portal vein thrombosis after splenectomy and esophagogastric devascularization for cirrhotic portal hypertension. J Hepatopancreatobiliary Surg. 2023;35(04):225–9. https://doi.org/10.11952/j.issn.1007-1954.2023.04.006 . (in China).
doi: 10.11952/j.issn.1007-1954.2023.04.006
Bagheri LK, Homayon K, Motevalli D, et al. Risk factors for portal vein thrombosis in patients with cirrhosis awaiting liver transplantation in Shiraz, Iran. Hepat Mon. 2015;15(12):e26407. https://doi.org/10.5812/hepatmon.26407 .
doi: 10.5812/hepatmon.26407
Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–805. https://doi.org/10.1177/0962280216669183 .
doi: 10.1177/0962280216669183
pubmed: 27683581
Wu Z, Xiao Y, Wang Y. Portal vein thrombosis in liver cirrhosis: an updated overview. Port Hypertens Cirrhos. 2023;2:78–91. https://doi.org/10.1002/poh2.46 .
doi: 10.1002/poh2.46
Baiges A, Procopet B, Silva-Junior G, et al. Incidence and factors predictive of recurrent thrombosis in people with non-cirrhotic portal vein thrombosis. J Hepatol. 2023;78(1):114–22. https://doi.org/10.1016/j.jhep.2022.08.023 .
Pradhan-Sundd T, Gudapati S, Kaminski TW, Ragni MV. Exploring the Complex Role of Coagulation Factor VIII in Chronic Liver Disease. Cell Mol Gastroenterol Hepatol. 2021;12(3):1061–72. https://doi.org/10.1016/j.jcmgh.2021.02.014 .
Lewis CS, Bari K, Xie C, et al. Potential utility of a multi-component coagulation factor panel to calculate MELD scores and assess the risk of portal vein thrombosis in chronic liver disease. BMC Gastroenterol. 2023;23(1):65. https://doi.org/10.1186/s12876-023-02695-6 .
doi: 10.1186/s12876-023-02695-6
pubmed: 36894870
pmcid: 9999630
Zermatten MG, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to Fibrinolysis. Hepatology. 2020;71(6):2135–48. https://doi.org/10.1002/hep.31201 .
doi: 10.1002/hep.31201
pubmed: 32090357
Kalambokis GN, Oikonomou A, Christou L, et al. Von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol. 2016;65(5):921–8. https://doi.org/10.1016/j.jhep.2016.06.002 .